Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Cyclerion Therapeutics (CYCN) has 3 years of Operating Leases data on record, last reported at $38.1 million in Q1 2021.

  • For Q1 2021, Operating Leases fell 19.1% year-over-year to $38.1 million; the TTM value through Mar 2021 reached $38.1 million, down 19.1%, while the annual FY2020 figure was $38.9 million, 44.78% down from the prior year.
  • Operating Leases reached $38.1 million in Q1 2021 per CYCN's latest filing, down from $38.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $72.4 million in Q2 2019 and bottomed at $38.1 million in Q1 2021.
  • Average Operating Leases over 3 years is $53.1 million, with a median of $46.7 million recorded in 2020.
  • Peak YoY movement for Operating Leases: crashed 44.78% in 2020, then dropped 19.1% in 2021.
  • A 3-year view of Operating Leases shows it stood at $70.5 million in 2019, then plummeted by 44.78% to $38.9 million in 2020, then fell by 2.22% to $38.1 million in 2021.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $38.1 million in Q1 2021, $38.9 million in Q4 2020, and $39.8 million in Q3 2020.